Impact of Cotrimoxazole Prophylaxis for HIV-Infected Adults on Antifolate Resistance
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
At least three studies in sub-Saharan Africa have demonstrated a decrease in morbidity or mortality among HIV-infected adults who took daily cotrimoxazole (trimethoprim sulfamethoxazole) [CTX] prophylaxis. Because of the demonstrated beneficial effect, high tolerability and low cost of CTX, the United Nations Programme on HIV/AIDS (UNAIDS) recommends that HIV-infected persons with symptomatic HIV or depressed CD4 counts receive daily CTX. The effect of this recommendation on subsequent development of antimicrobial resistance to antifolates among important pathogens needs to be evaluated. The investigators measured the change in the prevalence of markers of antifolate resistance among P. falciparum, and the change in the prevalence of CTX resistance among S. pneumoniae, and E. coli in HIV-infected individuals receiving CTX daily prophylaxis. In addition, the investigators measured the change in the prevalence of naso-pharyngeal or oro-pharyngeal carriage of CTX resistant S. pneumoniae among children living in households where an HIV-infected adult was receiving CTX daily prophylaxis.
| Condition | Intervention | Phase |
|---|---|---|
|
HIV Malaria Diarrhea Pneumonia Opportunistic Infections |
Drug: Cotrimoxazole (trimethoprim sulfamethoxazole) |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Educational/Counseling/Training |
| Official Title: | An Evaluation of the Impact of Cotrimoxazole Prophylaxis for HIV-Infected Adults on the Development of Antifolate Resistance Among Plasmodium Falciparum, Streptococcus Pneumoniae, and Escherichia Coli |
- Change in Plasmodium falciparum molecular markers of antifolate resistance before and while taking daily CTX
- Change in nasopharyngeal pneumococcal resistance before and while taking daily CTX, and among children living in households where adults are taking daily CTX
- Change in commensal E. coli resistance before and while taking daily CTX
- To measure CTX-resistance among Salmonella and other enteric bacterial pathogens in patients with diarrhea in the study area
- To assess the efficacy of sulfadoxine-pyrimethamine (SP) treatment of breakthrough P. falciparum parasitemia and clinical malaria among HIV-infected persons taking daily CTX prophylaxis
- To measure sulfa metabolite levels in HIV-infected persons receiving daily CTX who develop a drug reaction, to determine if differing rates of metabolism contribute to the development of adverse reactions
- To assess the effect of daily CTX prophylaxis on the etiology of diarrheal diseases in HIV-infected persons
- To evaluate the serotype distribution of and immune response to colonizing pneumococci
- To assess the cause of diarrheal diseases among HIV-infected persons
- To measure the change in quality of life indicators among clients receiving daily CTX
| Estimated Enrollment: | 1478 |
| Study Start Date: | February 2002 |
| Estimated Study Completion Date: | November 2003 |
We conducted this study in Kisumu, Kenya where HIV prevalence is high and malaria is highly endemic. HIV infected and uninfected adults were assigned to receive daily CTX if CD4 cell count was <350, or daily multivitamin if CD4 cell count was >= 350 or if the client was HIV negative. All clients were then followed for a total of 6 months. At specified scheduled and sick visits, clients received a physical exam, blood smears, nasopharyngeal swabs and stool samples or rectal swabs. Samples collected at baseline and during follow-up were used to measure the change in CTX resistance among P. falciparum parasites, pneumococcus isolates, and commensal E. coli.
Eligibility| Ages Eligible for Study: | 15 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Clients presenting to the CRC HIV counseling and testing site in Kisumu were eligible for the study if they met the following inclusion criteria:
- 15 years of age or older
- Able to make all follow-up visits (i.e. do not plan to leave Kisumu during the next 6 months, are not homebound)
- Able to understand and give informed consent.
Exclusion Criteria:
Clients were not eligible for the study if they met any of the following exclusion criteria:
- Known allergic reaction to sulfa medications (i.e. CTX, sulfadoxine- pyrimethamine)
- Women in their first trimester of pregnancy or planning to become pregnant in the next 6 months
- Clients taking daily antibiotics for treatment of a chronic illness; or prophylaxis, excluding tuberculosis treatment.
Contacts and Locations More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00137657 History of Changes |
| Other Study ID Numbers: | CDC-NCID-3354, UR6/CCU018970-02-2, SSC#664 |
| Study First Received: | August 29, 2005 |
| Last Updated: | December 12, 2005 |
| Health Authority: | United States: Federal Government |
Keywords provided by Centers for Disease Control and Prevention:
|
HIV malaria E. Coli S. pneumoniae drug resistance |
antifolate opportunistic infections Africa Kenya East Africa |
Additional relevant MeSH terms:
|
Diarrhea Malaria Opportunistic Infections Pneumonia Signs and Symptoms, Digestive Signs and Symptoms Protozoan Infections Parasitic Diseases Infection Virus Diseases Lung Diseases Respiratory Tract Diseases Respiratory Tract Infections Folic Acid Antagonists |
Trimethoprim Sulfamethoxazole Trimethoprim-Sulfamethoxazole Combination Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Anti-Infective Agents Therapeutic Uses Anti-Infective Agents, Urinary Renal Agents Antimalarials Antiprotozoal Agents Antiparasitic Agents |
ClinicalTrials.gov processed this record on May 19, 2013